Can peripheral bloodγδT cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy

Aminobisphosphonates and Toll-Like Receptor Ligands: Recruiting Vγ9Vδ2 T Cells for the Treatment of Hematologic Malignancy

(2011) S. Kalyan et al.   CURRENT MEDICINAL CHEMISTRY

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

(2009) J. Gertner-Dardenne et al.   BLOOD

Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo

(2009) Anke J Roelofs et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy

(2009) Robert S. Weinstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bisphosphonates and Time to Osteonecrosis Development

(2009) P. K. Palaska et al.   ONCOLOGIST

Osteonecrosis of the jaw — Who gets it, and why?

(2008) Ian R. Reid   BONE

Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP

(2008) Anke J. Roelofs et al.   BRITISH JOURNAL OF HAEMATOLOGY

Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management

(2008) Sunil J Wimalawansa   Expert Opinion On Drug Safety

Identification of Microbial Biofilms in Osteonecrosis of the Jaws Secondary to Bisphosphonate Therapy

(2008) Parish P. Sedghizadeh et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw

(2008) Beatrice J Edwards et al.   LANCET ONCOLOGY